ResearcherKitasato UniversityActive in the last 2 years
Yoshiki Murakumo
Matched on ORCID iD 0000-0003-2843-8189; OpenAlex author ID A5090516235. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 0, last author 3)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 15
2022: 3 papers · 2023: none · 2024: 1 paper
Papers 4
- REV7 is involved in outcomes of platinum-based chemotherapy in pancreatic cancer by controlling the DNA damage response. Last author DOI 10.1111/cas.16044↗
- CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. Last author DOI 10.1007/s00428-021-03230-2↗
- N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-022-15196-5↗
- Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic … Last author DOI 10.1097/mpa.0000000000001975↗
Closest collaborators
The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Akihiro Tamaki · 3 shared papers, 2022–2024 · strength 0.47
- Paper REV7 is involved in outcomes of platinum-based chemotherapy in pancreatic cancer by controlling the DNA damage response. DOI 10.1111/cas.16044↗
- Paper Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With An… DOI 10.1097/mpa.0000000000001975↗
- Paper CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. DOI 10.1007/s00428-021-03230-2↗
- Masayoshi Tadehara · 3 shared papers, 2022–2024 · strength 0.47
- Paper REV7 is involved in outcomes of platinum-based chemotherapy in pancreatic cancer by controlling the DNA damage response. DOI 10.1111/cas.16044↗
- Paper Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With An… DOI 10.1097/mpa.0000000000001975↗
- Paper CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. DOI 10.1007/s00428-021-03230-2↗
- Kai Adachi · 3 shared papers, 2022–2024 · strength 0.47
- Paper REV7 is involved in outcomes of platinum-based chemotherapy in pancreatic cancer by controlling the DNA damage response. DOI 10.1111/cas.16044↗
- Paper Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With An… DOI 10.1097/mpa.0000000000001975↗
- Paper CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. DOI 10.1007/s00428-021-03230-2↗
- Wasaburo Koizumi · 2 shared papers, 2022 · strength 0.30
- Paper Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With An… DOI 10.1097/mpa.0000000000001975↗
- Paper CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer. DOI 10.1007/s00428-021-03230-2↗
- Chika Kusano · 1 shared paper, 2024 · strength 0.18
- Shinji Mii · 1 shared paper, 2022 · strength 0.14
- Atsushi Enomoto · 1 shared paper, 2022 · strength 0.14
- Ryota Chijimatsu · 1 shared paper, 2022 · strength 0.14
- Suguru Mitsufuji · 1 shared paper, 2022 · strength 0.14
- Yuichiro Doki · 1 shared paper, 2022 · strength 0.14
- Kazuhiko Ogawa · 1 shared paper, 2022 · strength 0.14
- Hidetoshi Eguchi · 1 shared paper, 2022 · strength 0.14
- Hirofumi Akita · 1 shared paper, 2022 · strength 0.14
- Shotaro Tatekawa · 1 shared paper, 2022 · strength 0.14
- Hideshi Ishii · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.